Member Directory

Clarametyx Biosciences is combating the formidable challenge of persistent antibiotic-resistant infections through an innovative technology platform that targets the biofilm – a protective layer around bacteria – to enable a more effective immune response or antibiotic intervention. The Columbus, Ohio-based company is building a dynamic pipeline of immune-enabling therapies and vaccines for chronic and recurrent bacterial infections associated with biofilms. Its lead candidate, CMTX-001, is a humanized monoclonal antibody in preclinical development for hospital-acquired pneumonia.